08/23/2026
A family history of pancreatic cancer and an inherited genetic mutation can change screening recommendations.
In this clip from our 2026 Symposium, Dr. Margaret Tempero explains that individuals with a BRCA2 mutation and a family history of pancreatic cancer may qualify for pancreatic cancer screening as part of their standard medical care.
She also highlights the PRECEDE Consortium, an international collaboration dedicated to improving pancreatic cancer early detection for people at hereditary risk. Participants contribute annual blood samples and clinical information to help researchers develop better screening tools, identify risk factors, and advance prevention strategies.
Research initiatives like PRECEDE are helping move us closer to detecting pancreatic cancer earlier when treatment has the greatest potential to make a difference.
Watch Dr. Tempero’s presentation “Prevention and Surveillance for Pancreatic Cancer”: https://pancreatic.org/symposium-speaker-spotlight-margaret-tempero-md-to-discuss-prevention-and-surveillance-for-pancreatic-cancer/
Learn more about PRECEDE: https://pancreatic.org/symposium-speaker-spotlight-diane-m-simeone-md-to-discuss-pancreatic-cancer-early-detection-consortium-precede/